Sohini Das

All stories by Sohini Das

'No preparedness planning, no accountability, no action plan'

'No preparedness planning, no accountability, no action plan'

Rediff.com1 days ago

'This government did not have any plan for safety stocks of essential medicines.'

Pharma industry posts 51.5% growth in April sales

Pharma industry posts 51.5% growth in April sales

Rediff.com1 days ago

When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.

Remdesivir black-market thrives as Covid cases rise

Remdesivir black-market thrives as Covid cases rise

Rediff.com3 days ago

Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das

Covid vaccine: Too early to say if booster dose needed

Covid vaccine: Too early to say if booster dose needed

Rediff.com30 Apr 2021

Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months

Covid vaccine could cost up to Rs 1000 in private market

Covid vaccine could cost up to Rs 1000 in private market

Rediff.com28 Apr 2021

While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.

A COVID-19 Vaccine Snapshot

A COVID-19 Vaccine Snapshot

Rediff.com28 Apr 2021

Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the criteria.

Shortage of key chemical from US hits Covaxin ramp-up plans

Shortage of key chemical from US hits Covaxin ramp-up plans

Rediff.com22 Apr 2021

'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

100 million Covaxin vaccines by Sept

100 million Covaxin vaccines by Sept

Rediff.com17 Apr 2021

The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.

'We will be prioritising vaccine only for India'

'We will be prioritising vaccine only for India'

Rediff.com14 Apr 2021

'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'

Serum, Bharat Bio seek govt funds to boost vaccine output

Serum, Bharat Bio seek govt funds to boost vaccine output

Rediff.com5 Apr 2021

Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.

Expert panel seeks more data on Sputnik V Covid vaccine

Expert panel seeks more data on Sputnik V Covid vaccine

Rediff.com2 Apr 2021

'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'

Sputnik V vaccine may be added to India's Covid armoury soon

Sputnik V vaccine may be added to India's Covid armoury soon

Rediff.com30 Mar 2021

'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).

Bharat Biotech's Krishna Ella wins Covaxin fight

Bharat Biotech's Krishna Ella wins Covaxin fight

Rediff.com22 Mar 2021

'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'

Low turnout forces govt to mull private rollout of Covid vaccine

Low turnout forces govt to mull private rollout of Covid vaccine

Rediff.com10 Feb 2021

Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.

Lupin aims to enter Chinese market in the next one year

Lupin aims to enter Chinese market in the next one year

Rediff.com8 Feb 2021

Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.

More Covid vaccine candidates get approval for clinical trials in India

More Covid vaccine candidates get approval for clinical trials in India

Rediff.com6 Feb 2021

Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.

More Indians will take vaccine if politicians do: Survey

More Indians will take vaccine if politicians do: Survey

Rediff.com5 Feb 2021

In India, Opposition parties along with healthcare professionals have urged the government, including Prime Minister Narendra Modi and top leaders, to take either of the Covishield or Covaxin doses, which could help in drastically reducing trust and fear issues amongst citizens., reports Sohini Das.

Why early applicant Pfizer's Covid vaccine is delayed

Why early applicant Pfizer's Covid vaccine is delayed

Rediff.com19 Jan 2021

Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.

Serum Institute may supply 400 million doses to Gavi-Covax

Serum Institute may supply 400 million doses to Gavi-Covax

Rediff.com19 Jan 2021

Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.

Next